Literature DB >> 12877116

The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective.

Steven Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12877116     DOI： 10.2174/138161281030900iv

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


× No keyword cloud information.
  5 in total

1.  Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.

Authors:  Nuran Bektas Serce; Andreas Boesl; Irina Klaman; Sonja von Serényi; Erik Noetzel; Michael F Press; Arno Dimmler; Arndt Hartmann; Jalid Sehouli; Ruth Knuechel; Matthias W Beckmann; Peter A Fasching; Edgar Dahl
Journal:  BMC Cancer       Date:  2012-12-13       Impact factor: 4.430

2.  Gene expression of fibrinolytic markers in coronary thrombi.

Authors:  Jostein Nordeng; Svein Solheim; Sissel Åkra; Hossein Schandiz; Pavel Hoffmann; Borghild Roald; Bjørn Bendz; Harald Arnesen; Ragnhild Helseth; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2022-04-29

3.  Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes.

Authors:  Anuradha Moirangthem; Banashree Bondhopadhyay; Mala Mukherjee; Arghya Bandyopadhyay; Narendranath Mukherjee; Karabi Konar; Shubham Bhattacharya; Anupam Basu
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

4.  Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.

Authors:  Hans-Ullrich Völker; Michael Weigel; Annette Strehl; Lea Frey
Journal:  Diagn Pathol       Date:  2018-08-31       Impact factor: 2.644

5.  Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.

Authors:  Maja Lampelj; Darja Arko; Nina Cas-Sikosek; Rajko Kavalar; Maja Ravnik; Barbara Jezersek-Novakovic; Sarah Dobnik; Nina Fokter Dovnik; Iztok Takac
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.